Fibronectin extracellular matrix plays a critical role in the microenvironment of cells. Loss of this matrix frequently accompanies oncogenic transformation, allowing changes in cell growth, morphology, and tissue organization. The HT1080 human ®brosarcoma cell line is de®cient in formation of ®bronectin matrix ®brils but assembly can be induced by the glucocorticoid dexamethasone. Here we show that ®bronectin assembly can also be restored by stimulation of a 5 b 1 integrin with activating antibody or with Mn 2+ suggesting that integrin activity is reduced in these cells. While dexamethasone promoted actin stress ®ber formation, actin ®laments remained cortical following Mn 2+ treatment showing that the dexamethasone eect is not due solely to cytoskeletal changes. HT1080 cells have one activated allele of N-ras and PD98059 inhibition of signaling from Ras through ERK increased ®bronectin matrix accumulation. Conversely, the p38 MAP kinase inhibitor SB203580 blocked induction of matrix and increased ERK phosphorylation. Thus, two MAP kinase pathways contribute to the control of integrin-mediated ®bronectin assembly. ERK activity and ®bronectin assembly were linked in three dierent ras-transformed cell lines but not in SV40-or RSV-transformed cells indicating that oncogenic Ras uses a distinct mechanism to down-regulate cell-®bronectin interactions.
Introduction
The extracellular matrix (ECM) communicates important behavioral cues that aect cell dierentiation, migration and other biological processes. Cancer cells often have abnormal interactions with the ECM due to alterations in integrin receptors, ECM ligands, matrix metalloproteinases or the cytoskeleton (Boudreau and Bissell, 1998; Keely et al., 1998; Varner and Cheresh, 1996) . Loss of ®bronectin matrix has long been correlated with acquisition of a transformed phenotype (Hynes, 1990; Hynes and Wyke, 1975) . Oncogenically transformed cells frequently show decreased synthesis and increased degradation of ®bronectin (Olden and Yamada, 1977) resulting in a reduction in ®bronectin matrix. Some features of the transformed phenotype can be reverted by addition of ®bronectin which increases adhesiveness and contact inhibition of growth (Hynes et al., 1977; Yamada et al., 1976) . Fibronectin receptor downregulation also correlates with transformation (Plantefaber and Hynes, 1989) . Correction of this reduction by overexpression of the a 5 b 1 integrin can restore interaction with surrounding ®bronectin, decreasing migration and growth in soft agar (Giancotti and Ruoslahti, 1990) .
Assembly of ®bronectin matrix is initiated by binding to cell surface integrin receptors (reviewed in Mosher, 1993; Schwarzbauer and Sechler, 1999; Wu, 1997) . Tethering of ®bronectin via integrin binding promotes intermolecular interactions between ®bronec-tin dimers leading to the formation and elongation of matrix ®brils. The rate of accumulation of ®bronectin matrix is somewhat dependent on the level of integrin activity as stimulation of a 5 b 1 integrin with the divalent cation Mn 2+ can increase the amount of stable matrix that is assembled . A continuous link from the ECM to the cytoskeleton results from coordination of ®bronectin ®bril assembly with reorganization of actin into stress ®bers (Hynes, 1990; . In addition matrix transduces outside-in signals that control cell growth, gene expression, and other intracellular processes (Bourdoulous et al., 1998; Sechler and Schwarzbauer, 1998; Sottile et al., 1998) .
Activating point mutations in H-ras, K-ras or N-ras can transform cells by making the GTPase insensitive to GAPs or increasing the exchange of GDP for GTP. These types of mutations are found in at least 30% of human cancers (Malumbres and Pellicer, 1998) . Ras signals through multiple mediators to impact numerous cellular processes. ras-transformed cells can show anchorage-independent growth, growth factor-independent proliferation, and alterations in ion transport, cell volume control and organization of the cytoskeleton (Barbacid, 1987; Meyer et al., 1991; Wahrman et al., 1985) . For example, the HT1080 human ®brosarcoma cell line which has one activated allele of N-ras (Hall et al., 1983; Rasheed et al., 1974) multiplies rapidly, has decreased contact inhibition of growth and lacks stress ®bers and ®bronectin matrix. Treatment of HT1080 cells with the glucocorticoid dexamethasone reverses some aspects of the transformed phenotype. The synthesis of ®bronectin is upregulated and it is assembled into ®brils (Oliver et al., 1983) . Exogenously supplied ®bronectin can also be assembled in a dexamethasone-dependent manner that requires new protein synthesis as it is blocked by cycloheximide (McKeown-Longo and Etzler, 1987) . Apparently, dexamethasone induces expression of a gene or genes that modulate the transformed phenotype of these cells.
Our analyses of the regulation of ®bronectin matrix assembly have identi®ed important roles for integrin activation and MAP kinase pathways. Inhibition of ERK activation or stimulation of integrin activity independently increased the level of ®bronectin ®bril formation. In addition our results indicate that insideout eects on integrin function from multiple signaling pathways regulate ®bronectin matrix assembly. The inverse correlation between ERK activity and ®bro-nectin assembly appears to be speci®c to ras-transformed cells.
Results

Dexamethasone increases fibronectin assembly but not integrin expression
Dexamethasone induces ®bronectin synthesis and matrix assembly by HT1080 ®brosarcoma cells (Oliver et al., 1983; McKeown-Longo and Etzler, 1987) . Untreated HT1080 cells assembled very few ®bronec-tin ®brils even in the presence of excess exogenous ®bronectin while extensive matrix ®brils were formed surrounding cells treated with dexamethasone ( Figure  1a ). Induction of matrix assembly was also assessed by monitoring the conversion of cell-associated, deoxycholate (DOC)-soluble ®bronectin ®brils into a DOC-insoluble network (McKeown-Longo and Mosher, 1983) . Figure 1b (top) shows that dexamethasone signi®cantly increased the incorporation of exogenous ®bronectin into both DOC-soluble and DOC-insoluble fractions. Dexamethasone also induced assembly of endogenously produced ®bronectin (Figure 1b, bottom) . However, increased availability of ®bronectin was not responsible for increased ®bril formation as untreated cells provided with excess exogenous ®bronectin did not assemble matrix ®brils ( Figure 1a ,b top) Induction of ®bronectin matrix assembly by dexamethasone was inhibited by cycloheximide (McKeown-Longo and Etzler, 1987) , indicating a requirement for new gene expression. As increased expression of integrins can improve adhesion to ECM, we tested the idea that dexamethasone was upregulating the synthesis of integrin receptors necessary for ®bronectin matrix assembly. Two ®bronectin binding integrins a 5 b 1 and a v b 3 are expressed by HT1080 cells (Grenz et al., 1993) . Adhesion and migration on ®bronectin can be blocked with anti-a 5 or anti-b 1 antibodies (Yamada et al., 1990 ) and antibodies to a 5 also block spreading on ®bronectin and matrix assembly induced by dexamethasone (data not shown) suggesting that a 5 b 1 is the major ®bronectin receptor on these cells. Immunoprecipitations from 35 S-methionine labeled cells showed no change in the levels of b 1 , a 5 or a v integrin subunits following dexamethasone treatment (Figure 2a ). To determine whether dexamethasone was inducing a relocalization of pre-existing integrin subunits to the cell surface,¯uorescence activated cell sorting was performed with an anti-a 5 antibody. No change in cell surface levels of a 5 b 1 was observed (Figure 2b ). These results demonstrate that induction of ®bronectin matrix assembly is dependent on expression of genes other than ®bronectin and integrins.
Direct integrin activation can stimulate fibronectin matrix assembly
Dexamethasone did not aect the levels of integrins on the cell surface. We considered that dexamethasone might alter the ability of integrins to bind and assemble ®bronectin into ®brils. Exogenous agents like the divalent cation Mn 2+ and b 1 stimulatory antibodies bind to integrin extracellular domains and upregulate integrin activity (Gailit and Ruoslahti, 1988; Hemler et al., 1984) . Incubation of HT1080 cells with exogenous ®bronectin and 1 mM MnCl 2 or the anti-b 1 antibody TS2/16 enhanced assembly of a ®brillar matrix similar to the matrix induced by dexamethasone (Figure 3a) . These matrices contained signi®cant amounts of DOC-insoluble material ( Figure  3b ). Thus, like dexamethasone treatment, stimulation of integrin binding to ®bronectin also induces matrix assembly. The eects of dexamethasone on matrix assembly are likely to be the result of new gene expression altering integrins via an inside-out signaling mechanism. HT1080 cells have one activated N-ras allele (Hall et al., 1983) and ras-transformation is known to aect actin organization (Bar-Sagi and Feramisco, 1986) . Untreated HT1080 cells showed mainly cortical actin localization ( Figure 4a ). Dexamethasone treatment resulted in a reorganization of actin into stress ®bers and increased cell spreading (Figure 4c ) supporting the idea that this treatment reverts some of the transformed properties of the ®brosarcoma cells and modulates the eects of excessive Ras signaling. Dexamethasone was also found to induce a relocalization of another cytoskeletal protein, caldesmon, onto stress ®bers (not shown). In contrast, matrix assembly induced by agents that act on the extracellular domain of the integrin receptors did not have a signi®cant impact on actin organization. Following treatment with Mn shown), actin remained predominantly cortical. Fibronectin matrix assembly can apparently proceed without a major contribution from actin stress ®bers.
Intracellular regulation of matrix assembly
Activated Ras signaling has been shown to suppress integrin function (Hughes et al., 1997) . Stimulation of HT1080 integrins induced ®bronectin ®bril formation suggesting that matrix assembly was downregulated by N-ras signaling through MAP kinases. To test this idea, the eects of inhibitors that speci®cally block signaling through ERK and p38 MAP kinase pathways were determined. HT1080 cells were treated with PD98059, an inhibitor of MEK1 phosphorylation of ERK1 and 2 (Dudley et al., 1995) . PD98059 signi®cantly upregulated formation of ®bronectin ®brils ( Figure 5a ) and levels of DOC-insoluble ®bronectin matrix (Figure 5b ). In contrast, SB203580, an inhibitor of p38 MAP kinase (Young et al., 1997) , did not increase ®bronectin assembly (Figure 5c ). In fact, formation of DOC-insoluble matrix induced by dexamethasone ( Figure 5c ) but not Mn 2+ (data not shown)
was dramatically reduced when cells were simultaneously treated with SB203580. To verify that PD90859 was acting to decrease ERK activity in these cells, a kinase assay was performed. ERKs from treated and untreated cells were immunoprecipitated and incubated with MBP substrate plus [g-32 P]ATP. Counts incorporated into the substrate were compared. Lysates from PD98059 treated cells showed an approximately 70% reduction in ERK activity ( Figure 6a ) and decreased levels of phosphorylated ERK by immunoblotting with anti-phospho ERK antibodies (Figure 6b ). Dexamethasone did not alter ERK phosphorylation suggesting that its eects on matrix assembly are downstream of the MAP kinase. In contrast to the result with PD98059, ERK phosphorylation was increased signi®cantly by treatment with SB203580 ( Figure 6b) . Thus, inhibition of these two pathways has opposite eects on ®bril formation.
To determine whether MAP kinase signaling accounts for reduced ®bronectin matrix in other transformed cells, we compared the eects of MAP kinase inhibition on cells transformed with ras, SV40, or RSV. T24 H-ras transformed human bladder carcinoma cells, ras-transformed 3T3 cells (EJ-Bam), SV40-transformed 3T3 cells (SVT2) and RSV-transformed Rat1 cells were treated with PD98059 and DOC-insoluble material was analysed. All three rastransformed cells, EJ-Bam, T24 and HT1080, showed increased ®bronectin matrix following treatment with Immunoblots for activated ERK2 were performed on lysates from untreated cells or those grown for 2 h in 25 mM PD98059, 10 mM SB203580, 1 mM dexamethasone or both SB203580 and dexamethasone. Parallel blots showed equal levels of ERK protein under all conditions (not shown). The upper band of the doublet is p44/ERK1 and the lower band is p42/ERK2 (Kohno, 1985) PD98059 (Figure 7) . Similar results were seen when the T24 cells were treated with dexamethasone. In contrast, the level of matrix was not altered following inhibition of MEK1 in SV40 (Figure 7) or RSV (not shown) transformed cell lines. Therefore, ras-transformed cells regulate ®bronectin matrix levels through changes in ERK signaling while alternative mechanisms for controlling ®bronectin matrix assembly are activated by other transforming agents.
Discussion
Fibronectin matrix assembly is a regulated process that requires binding to integrin receptors and induction of ®bronectin-®bronectin interactions for ®bril formation. Intracellular events also play a regulatory role in this process. While HT1080 cells make ®bronectin, they do not assemble ®brils without dexamethasone treatment. Our analyses of the block in matrix assembly have revealed important features of the regulatory mechanism in these cells. (1) Matrix assembly was induced by exogenous stimulation of integrins with either Mn 2+ or b 1 stimulatory antibody indicating that integrin activity in these cells is insucient to form ®bronectin into ®brils. (2) Inhibition of ERK MAP kinase activation enhanced ®bronectin assembly. Given that active Ras has been shown to suppress integrin function, this indicates that activated N-Ras down-regulates HT1080 matrix formation through eects on integrin activity. (3) At least one other MAP kinase pathway contributes to this process. Our results show that inhibition of p38 MAP kinase ablates dexamethasone-induced assembly. (4) Reduction of ®bronectin matrix through Ras activity appears to be a general feature of rastransformed cells while other transforming agents down-regulate ®bronectin matrix via dierent mechanisms. Thus, the development of an oncogenic phenotype through mutations in ras acts via intracellular signals that control cell interactions with the ECM.
Decreased ®bronectin matrix has been observed in numerous tumors and tumor-derived cell lines (Hynes, 1990) . In most cases, loss of matrix results from decreased expression of ®bronectin or its receptors.
Here we have shown that intracellular conditions aecting integrin activity can prevent ®bronectin matrix assembly. HT1080 cells are able to adhere to ®bronectin without dexamethasone stimulation (Oliver et al., 1983; Yamada et al., 1990 Hughes et al. (1997) showing that overexpression of H-Ras suppressed activation of integrins in CHO cells. Clearly, excessive Ras signaling can have a negative impact on integrin activity. On the other hand, integrin ligation has been shown to induce Ras signaling (Kapron-Bras et al., 1993; Morino et al., 1995; Schlaepfer et al., 1994) . Perhaps an intermediate level of signaling from Ras is necessary for matrix assembly and this level is attained through a regulatory feedback loop similar to the one identi®ed for PDGF. PDGF binding to its receptor activates Ras which in turn down-regulates the PDGF receptor in two dierent ways: by decreasing transcription of the receptor and by increasing levels of a receptor inhibitor (Stice et al., 1999) . Ras-dependent cycles of integrin stimulation and inhibition may be important to temporarily suspend matrix assembly in order for cells to proliferate and migrate.
Reducing ERK phosphorylation with a MEK1 inhibitor increased the amount of ®bronectin matrix in three ras-transformed cell lines. As we do not observe signi®cant decreases in phosphorylation of ERKs following dexamethasone treatment, it seems likely that dexamethasone is acting downstream of ERKs. Dexamethasone is a potent transcriptional regulator (Furcht et al., 1979; Mader and White, 1993; Uht et al., 1997) and the ability of cycloheximide to inhibit the eect of dexamethasone (McKeownLongo and Etzler, 1987) suggests altering gene expression is important for regulating integrin function and thus ®bronectin assembly. A correlation between changes in phosphatase levels and MAP kinase activity has been reported in an osteoblast cell line after treatment with dexamethasone (Hulley et al., 1998) . Possibly induction of phosphatases by dexamethasone treatment of HT1080 cells leads to dephosphorylation of MAP kinases or one of their downstream targets. Another candidate gene is Rho since increased levels of Rho protein in ras-transformed cells have recently been observed following dexamethasone treatment (Moustakas and Stournaras, 1999) . Rho activity aects the actin cytoskeleton and increases cell contractility, both of which contribute to ®bronectin assembly (Zhang et al., 1994; Zhong et al., 1998) . However, treatment of HT1080 cells with LPA, which is known to activate Rho in other cells, did not increase the amount of ®bronectin matrix (unpublished observations).
While decreasing ERK activation increased matrix production, treatment with SB203580, which blocks Figure 7 Eects of MEK1 inhibitor are speci®c to rastransformed cells. HT1080, T24, EJ-Bam and SVT2 cells were treated (PD) or not (U) with 25 mM PD98059 for 24 h. DOCinsoluble fractions were assessed for ®bronectin matrix by immunoblotting using HFN 7.1 p38 MAP kinase activity, increased ERK activation and decreased matrix assembly. Both of these MAP kinases are activated by serum growth factors such as PDGF (Seuerlein et al., 1996; Matsumoto et al., 1999) and serum-deprived cells formed a modest but detectable DOC-insoluble ®bronectin matrix in the absence of dexamethasone (unpublished observations). In accordance with our results, others have reported dual contributions from ERK and p38 MAP kinase pathways to a variety of cellular processes. For example, active p38 MAP kinase inhibited ERKdependent LDL receptor expression (Singh et al., 1999) , a mechanism similar to the opposite eects of these MAP kinases on matrix assembly. Involucrin transcription (E®mova et al., 1998) and ®bronectin-mediated control of matrix metalloprotease expression (Esparza et al., 1999 ) also require input from both of these pathways. Of signi®cant relevance to our ®ndings is the proposal that, in addition to the activation of ERK, other pathways contribute to the Ras-induced suppression of integrin function (Hughes et al., 1997) . Our results suggest the possibility that one of these other pathways involves p38 MAP kinase. Mn 2+ treatment previously has been shown to stimulate adhesion via integrins (Gailit and Ruoslahti, 1988; Mould et al., 1995) . Furthermore, the rate of ®bronectin ®bril growth and conversion to DOCinsoluble material by CHOa 5 cells was increased in the presence of Mn 2+ . Our results suggest that a threshold level of integrin activity is required for matrix assembly as HT1080 cells attached to ®bronectin without treatment but required stimulation for ®bril formation. Interestingly, while the restoration of matrix by dexamethasone was accompanied by a dramatic increase in actin stress ®bers, actin ®laments remained predominantly cortical following Mn 2+ stimulated assembly. Stress ®bers allow cell contraction and provide tension for formation and remodeling of ®brils (Zhang et al., 1994 (Zhang et al., , 1997 Zhong et al., 1998) . The actin reorganization induced by dexamethasone may contribute to ®bril formation by providing structural support for the developing matrix or by aiding in the relocalization of cytoplasmic proteins to sites of integrin-®bronectin engagement. However, ®bril formation progressed quite eciently in Mn 2+ -treated cells lacking signi®cant numbers of actin stress ®bers suggesting that connections to cortical actin ®laments may be sucient to provide the cytoskeletal framework necessary for assembly.
Cellular controls exerted by FN matrix are decreased in most transformed cell types (Hynes, 1990) . Virally, chemically, and spontaneously transformed cells usually have less surface ®bronectin than their normal counterparts. Several mechanisms for decreasing ®bro-nectin have been demonstrated. Transforming agents such as RSV have been shown to reduce FN biosynthesis (Olden and Yamada, 1977; Stone et al., 1974) . Decreased integrin receptor expression (Plantefaber and Hynes, 1989) and increased degradation of ®bronectin (Hynes and Wyke, 1975; Olden and Yamada, 1977) have also been observed. Our results show that ras-transformed cells use another mechanism to modulate the level of ®bronectin matrix, namely, down-regulation of integrin receptor activity. Clearly, multiple distinct mechanisms are available to prevent cell-ECM interactions thus rendering cells tumorigenic.
Materials and methods
Antibodies, cells and reagents
MnCl 2 , cycloheximide, PDGF and dexamethasone were purchased from Sigma Chemical Co. PD98059 and SB203580 were from Calbiochem. Monoclonal antibodies were used as culture supernatants and included anti-b 1 stimulatory mAb TS2/16 kindly provided by Martin Hemler (Harvard Medical School) (Hemler et al., 1984) , anti-human ®bronectin antibody HFN 7.1 from ATCC and anti-a 5 mAb BIIG2 kindly provided by Caroline Damsky (UCSF) (Damsky et al., 1992; Werb et al., 1989) . Polyclonal antisera against b 1 , a 5 and a v integrin cytoplasmic domains were generous gifts of Richard Hynes (MIT) (a 5 and b 1 ) and Lou Reichardt (UCSF) (a v ). R457 is a polyclonal antiserum raised against the amino terminal 70 kD fragment of ®bronectin (Aguirre et al., 1994) . Anti-ERK2 rabbit polyclonal IgG was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) (#sc-154), anti-phospho ERK2 was from New England Biolabs (Beverly, MA, USA) (#9101). HT1080 human ®brosarcoma cells, EJ-Bam Ras transformed 3T3 cells and T24 bladder carcinoma cells were obtained from ATCC. HT1080 cells were grown in DMEM with 10% fetal calf serum (Hyclone, Logan, UT, USA). SV40 transformed SVT2 cells (Schwarzbauer et al., 1989) and EJ-Bam cells were grown in DMEM with 10% calf serum. RSV-transformed Rat1 cells were grown in DMEM with 5% calf serum and T24 cells were grown in McCoy's 5A media with 10% fetal calf serum.
Integrin immunoprecipitations and flow cytometry
Cells were metabolically labeled in 25 mCi/ml of 35 Smethionine for 24 h in the presence or absence of 1 mM dexamethasone. Lysis was in a buer containing 50 mM TrisHCl, pH 8, 150 mM NaCl, 0.5 mM CaCl 2 and 0.5% NP40. Immunoprecipitations were performed as described (Marcantonio and Hynes, 1988) . Immunoprecipitates were electrophoresed non-reduced on a 6% polyacrylamide-SDS gel, dried and analysed using a Molecular Dynamics PhosphorImager.
For¯ow cytometry, cells were grown 30 h with or without 1 mM dexamethasone, removed from the plate with 0.1 mg/ml TPCK-trypsin and washed with 0.5 mg/ml soybean trypsin inhibitor (both from Sigma, St Louis, MO, USA). Cells were resuspended at 1610 7 per ml in PBS containing 2% ®bronectin-depleted calf serum and 1 mM azide, incubated for 30 min with BIIG2 culture supernatant (1 : 3), followed by a 30 min incubation with Molecular Probes¯uorescein goat antimouse IgG (1 : 5000) for analysis by FACS using Cell Quest Software (Becton Dickinson, Franklin Lakes, NJ, USA).
Immunofluorescence
Cells were seeded on glass coverslips in 24-well dishes at 3610 5 cells per well. Cells were plated with 1 mM dexamethasone, 230 ml TS2/16 or 25 mM PD98059 for 24 h, or with 1 mM MnCl 2 for 4 h. In some experiments 50 mg/ml ®bronectin was added to the media along with the treatment. For PDGF experiments cells were grown in 10% serum, no serum or 40 ng/ml PDGF for 24 h before addition of ®bronectin for 6 h. After treatment, coverslips were ®xed in 3.7% formaldehyde in PBS followed by staining either with HFN 7.1 antibody diluted 1 : 10 and¯uorescein goat antimouse IgG diluted 1 : 600 or with rhodamine phalloidin diluted 1 : 1000 . Polyclonal antiserum R457 to the 70 kD domain of ®bronectin was used for staining in cells treated with the monoclonal stimulatory antibody TS2/16. Coverslips were mounted onto microscope slides with Slow-Fade (Molecular Probes, Eugene, OR, USA). Staining was visualized with a Nikon Optiphot-2 microscope and images were captured using an Optronics three sensor CCD camera and Adobe Photoshop software.
Isolation and characterization of DOC-soluble and DOCinsoluble fibronectin
Cells were seeded at 3610 5 cells per well in 24-well dishes and treated as for immuno¯uorescence above. SB203580 was used at 10 mM, PDGF at 40 ng/ml. Cells were lysed in 200 ml of DOC buer (2% deoxycholate, 20 mM Tris-HCl, pH 8.8, 2 mM PMSF, 2 mM EDTA, 2 mM iodoacetic acid and 2 mM N-ethylmaleimide). DOC-insoluble material was isolated by centrifugation and solubilized in SDS buer (1% SDS, 25 mM Tris-HCl pH 8, 2 mM PMSF, 2 mM EDTA, 2 mM iodoacetic acid and 2 mM N-ethylmaleimide) (Sechler et al., 1996) . Protein concentration was determined using BCA Assay (Pierce, Rockford, IL, USA). Aliquots containing equal amounts of total protein from either DOC-soluble or DOC-insoluble fractions were reduced with DTT and resolved by 5% polyacrylamide-SDS gel electrophoresis. Proteins were transferred to nitrocellulose (Sartorius Corp., Bohemia, NY, USA) and probed with HFN 7.1 culture supernatant diluted 1 : 100, followed by horseradish peroxidase conjugated goat anti-mouse secondary antibody (Pierce) diluted 1 : 50 000 and developed with SuperSignal ECL reagents (Pierce).
Detection of ERK phosphorylation
For kinase assays cells were grown 24 h with or without 25 mM PD98059. Cells were lysed in 50 mM Tris-HCl pH 7.5, 250 mM NaCl, 2 mM EDTA, 1% NP40, 1 mM PMSF, 50 mM NaF, 0.1 mM Na 3 VO 4 , 10 mg/ml aprotinin, and 10 mg/ml leupeptin. Protein concentrations of lysates were quanti®ed using BCA Assay (Pierce). One hundred and ®fty mg of each lysate was incubated with 20 ml ERK2 antibody overnight followed by a 2 h incubation with protein A agarose (RepliGen). Bound material was washed three times in lysis buer and twice in kinase buer (50 mM Tris-HCl pH 7.5, 10 mM MgCl 2 ) then incubated 30 min at 308C in 25 mM ATP, 0.03 mg/ml Myelin Basic Protein and 10 mCi[g-32 P]-ATP in 100 ml kinase buer and stopped using 26SDS loading buer (Zhu et al., 1996) . Samples were run on 12% polyacrylamide-SDS gel, exposed to a PhosphorImager screen and analysed using Image Quant Software.
For phospho-ERK immunoblotting, cells were seeded at 5610 5 cells per 35-mm well and grown for 24 h. Ten mM SB203580, 25 mM PD98059 and 1 mM dexamethasone were added as indicated 2 h before lysis in 1% Triton X-100, 5 mM EDTA, 50 mM NaCl, 50 mM NaF, 0.1% BSA, 1% aprotinin, 10 mM Tris, pH 7.6 and 1 mM PMSF according to the procedure of Kazlauskas and Cooper (1988) . Fifteen mg samples were electrophoresed through a 10% polyacrylamide-SDS gel and probed with an anti-phospho ERK antibody (New England Biolabs) diluted 1 : 1000 following 10% SDS ± PAGE. In parallel cell lysates were immunoblotted with anti-ERK antibody (Santa Cruz) diluted 1 : 1500 to control for equal protein levels.
